Skip to content
OpenCapital
Get started

JBIO JBIO Shares (Diluted)

Shares (Diluted) at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
256.3M-1.2%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
91.9M+4.0%
Vera Therapeutics logo
Vera TherapeuticsVERA
71.5M+12.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
28.7M-6.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
20.1M+91.2%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
58.3M+36.5%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K—
Free cash flow-$33.7M—

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B—

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity0×—
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's shares (diluted)?
JBIO (JBIO) reported shares (diluted) of 57.8M in Q1 2026.
How has JBIO's shares (diluted) changed year-over-year?
JBIO's shares (diluted) increased by 1731.0% year-over-year, from 3.2M to 57.8M.
What is the long-term trend for JBIO's shares (diluted)?
Over 3 years (2022 to 2025), JBIO's shares (diluted) has grown at a 1.6% compound annual growth rate (CAGR), from 97.7M to 102.5M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.